{
    "clinical_study": {
        "@rank": "104035", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Group", 
                "arm_group_type": "Experimental", 
                "description": "treat by moxibustion and acupuncture"
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Experimental", 
                "description": "treat by Sham acupuncture and moxibustion"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether acupuncture or moxibustion therapies are\n      effective in the treatment of active Crohn's disease. meanwhile, we are aim to observe the\n      content of Inflammatory factors and Neurotransmitter before and after acupuncture and\n      moxibustion therapy."
        }, 
        "brief_title": "Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Crohn's Disease", 
            "CAM"
        ], 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to determine whether acupuncture or moxibustion therapies are\n      effective in the treatment of active Crohn's disease. meanwhile, we are aim to observe the\n      content of Inflammatory factors and Neurotransmitter before and after acupuncture and\n      moxibustion therapy.\n\n      Through treating active Crohn's disease by acupuncture and moxibustion therapies for 12\n      weeks, we are aim to observe the efficiency and the probably change of Inflammatory factors\n      and Neurotransmitter of colonic mucosa and we may elucidate the mechanism of the efficiency\n      of acupuncture and moxibustion therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18-70 years;\n\n          -  Crohn's Disease Activity Index [CDAI]\uff1e150 and \uff1c450;\n\n          -  not taking any medication or taking salicylates, prednisone ( dose\u2264 15mg and at least\n             have taken a month ), after entering the study the dose remained constant;\n\n          -  Not taking immunosuppressive agents or use \" with \" biological preparations within 3\n             months prior to entering the study\n\n          -  signing a written informed consent form.\n\n        Exclusion Criteria:\n\n          -  Severe Crohn's disease patients or patients in remission ( CDAI > 450 or < 150 );\n\n          -  The pregnancy or lactation period patients ;\n\n          -  patients associated with heart, brain, liver, kidney and hematopoietic system\n             disease;\n\n          -  The psychiatric patients;\n\n          -  Patients with other serious diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697761", 
            "org_study_id": "SHACU-201202"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment Group", 
                "description": "patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes\uff0c3 times a week for 12 weeks", 
                "intervention_name": "Treatment Group", 
                "intervention_type": "Other", 
                "other_name": [
                    "acupuncture and moxibustion group", 
                    "acupuncture and Herbs-partitioned moxibustion group"
                ]
            }, 
            {
                "arm_group_label": "Control Group", 
                "description": "patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.", 
                "intervention_name": "Control Group", 
                "intervention_type": "Other", 
                "other_name": "Sham acupuncture and moxibustion group"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Crohn's disease,acupuncture,moxibustion,inflammation factors", 
        "lastchanged_date": "October 1, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200030"
                }, 
                "name": "Shanghai Institute of Acupuncture-Moxibustion and Merdian"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease and Its Regulation Mechanism to the Immune Homeostasis Mediated by Th17/Treg Cells", 
        "overall_official": {
            "affiliation": "Shanghai Institute of Acupuncture, Moxibustion and Meridian", 
            "last_name": "Wu Huangan, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "China: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Crohn's Disease Activity Index", 
            "measure": "CDAI", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Intestinal mucosa of Th17/Treg,IL-6,IL-17,IL-23,etc", 
                "measure": "Inflammatory factors", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Intestinal mucosa of 5-HT,DA,SP,VIP and their receptors etc", 
                "measure": "Neurotransmitter", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Inflammatory Bowel Disease Questionnaire", 
                "measure": "IBDQ", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Shanghai Institute of Acupuncture, Moxibustion and Meridian", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Institute of Acupuncture, Moxibustion and Meridian", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}